CN105213456A - A kind of anti-fatigue medicament and its production and use - Google Patents
A kind of anti-fatigue medicament and its production and use Download PDFInfo
- Publication number
- CN105213456A CN105213456A CN201510763099.5A CN201510763099A CN105213456A CN 105213456 A CN105213456 A CN 105213456A CN 201510763099 A CN201510763099 A CN 201510763099A CN 105213456 A CN105213456 A CN 105213456A
- Authority
- CN
- China
- Prior art keywords
- fatigue
- fatigue medicament
- medicament
- oral
- panacis quinquefolii
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The invention discloses a kind of anti-fatigue medicament and its production and use, by Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction, experimental result shows, have and extend middle age and Aged Mice walking weight load, increase liver glycogen reserves, reduce lactic acid, urea nitrogen content, have that consumption is little, safety, injectable, can be oral etc. advantage, there is larger health care and clinical value.This anti-fatigue medicament provided by the invention can be applicable to prepare anti-fatigue health-product containing or food.
Description
Technical field
The present invention relates to biotechnology medicine food dual-purpose plant field, particularly a kind of anti-fatigue medicament and its production and use.
Background technology
Fatigue is a kind of sense of discomfort of subjectivity; main manifestations is feeling of fatigue, taediumvitae; can perceive working for a long time, under strenuous exercise or long-time stress; this is a kind of normal physiological protective reaction; prompting body should make functional recovery by rest, thus avoids the further injury to health.But along with the aggravation of social competition, the quickening of rhythm of life, makes people usually ignore fatigue, still select to work long hours.Be in fatigue state for a long time, meeting insulting muscle power, physical ability, health is unbalance, makes people be difficult to be engaged in or complete some comparatively large or that action is fine and smooth, the exquisite work that consumes one's strength, thus makes work efficiency drop; On the other hand, chronic fatigue also can make application on human skin relax, and lusterless complexion, presents the sign of geromorphism; Chronic fatigue can not get recovering, and make human immune system's functional disorder, even cause immunocompromised, the barrier of body resist the disease is broken, and the probability of patient is increased.In addition, long-term mental pressure, hormone disturbance, dysimmunity etc. are all the main inducing causing chronic fatigue syndrome.The work of over loading, excessive pressure and erratic daily life system make people usually feel, and feeling of fatigue, taediumvitae are difficult to recover for a long time, people are made to be in sub-health state for a long time, the people of 70% is about had to be in this state in crowd, wherein occurred frequently with middle-aged and elderly people again.
Based on this; need to find resisting fatigue material to delay long-time work, strenuous exercise or the fatigue that excessively causes under stress occurs; or make fatigue state return to normal condition as early as possible, recover normal to making people's sub-health state or curative effect is produced to fatigue syndrome.Existing anti-fatigue medicament is mainly based on Chinese medicine, and feature focuses on health preserving, and consumer needs long-term taking, and onset is slow.
Therefore, a kind of new anti-fatigue medicament is provided to have realistic meaning.
Maca (Maca) full name Lepidium meyenii (LepidiummeyemiiWalp), is the annual or 2 years raw herbaceous plant of Cruciferae separate row Vegetable spp, originates in the mountain area, Andean of more than height above sea level 4000m in the middle part of Peru.Because Maca is low temperature resistant, strong wind, can grow under severe ecological condition, become one of local chief crop.The main Leaf-feeding insects of Maca is Maca root, storage root diameter 2 ~ 5cm that underground is expanded, and surface color is mostly yellow or purple, and meat white or faint yellow, has penetrating odor and special butterscotch abnormal smells from the patient.The high place of production (cultivation product are main) of current Maca is still at Ka Huama fertile land district, Andes (Carhuamayo) and Hu Ningqu (Junin).Be high and cold, the high wind of height above sea level 4000 ~ 4500m and high Rizhao Area Maca suitable growth.
On South America Peru and other places, can fry edible during Maca root using fresh herb together with meat or other vegetable, then i.e. edible is boiled with water or milk after drying, for thousands of years Maca root as food and medical herbs for strengthening energy, resisting fatigue, improvement function, improves fertility, treatment female climacteric syndrome etc.
Cordyceps militaris, have another name called Cordyceps militaris (L.) Link., in 1958 at Jilin Province's Late Cambrian, be tested and appraised, think that it and Cordyceps are same genus, main product, in Yunnan (Kunming, peacefulness, river and mountain), Jilin (Antu, Yongji), Liaoning (Shenyang), the Inner Mongol (Zhelimu League), is born on the pupal cell of lepidopteran insects in pin, broad-leaf forest or mixed forest surface soil layer.Can adopt the manually batch cultivation of silkworm and Antheraea pernyi Geurin Meneville, drug effect, pharmacology are similar to wild species even better.
Cordyceps fungus is a kind of bioreactor, no matter makes how to produce, and the bioactive substance of its synthesis is the same.The health care of these bioactive substances is identical with medical value.Cordycepin, cordycepic acid and Cordyceps polysaccharide are winter worms
The distinctive material of summer grass bacterium is the leading indicator of Cordyceps special efficacy.And these indexs exactly, the Cordyceps militaris (L.) Link. content grown under the affluent condition of artificial environment can grow get Geng Gao than under natural endowment.The protein of the Cordyceps militaris (L.) Link. of artificial culture, aminoacid, vitamin equal size all meet or exceed the level of natural cordyceps.Although the indivedual nutritional labelings in the Cordyceps militaris (L.) Link. of artificial culture are a little less than natural cordyceps level, these nutritional labelings can be improved by research.
Radix Panacis Quinquefolii (formal name used at school: Panaxquinquefolius) is Araliaceae Panax herbaceos perennial, another name Radix Panacis Quinquefolii, Radix Panacis Quinquefolii, Western Radix Ginseng, Americanginseng, originate in the Wisconsin State of Canadian large Quebec and the U.S., also there is plantation on the ground such as Huairou, BeiJing, China and Changbai Mountain.What Canada produced is Radix Panacis Quinquefolii, and what the U.S. produced is Radix Panacis Quinquefolii, instructions of taking be divided into boil, stew, steamed wheaten foods, section contain change, be ground into fine powder takes after mixing it with water.
Radix Panacis Quinquefolii has YIN nourishing and QI supplementing, the mind calming and mentality promoting and clearing away heat and promoting production of body fluid, the double effects that pathogenic fire reducing is relieved summer heat.Archaism cloud: " Radix Panacis Quinquefolii is cool in nature and mend, all wish Radix Ginsengs and not by Radix Ginseng warm person all can with it ".Therefore mend and not dry be the special feature of Radix Panacis Quinquefolii.
1, the mobility of strengthening cardiac muscle and enhancing heart.
2, strong nervus centralis, stable body and mind also sets up, and have calmness and antialcoholism action, hypermnesis ability, has remarkable efficacy to Alzheimer.
Summary of the invention
In view of this, the object of this invention is to provide a kind of anti-fatigue medicament, by Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction, experimental result shows, have and extend middle age and Aged Mice walking weight load, increase liver glycogen reserves, reduce lactic acid, urea nitrogen content, have that consumption is little, safety, injectable, can be oral etc. advantage, there is larger health care and clinical value.This anti-fatigue medicament provided by the invention can be applicable to prepare anti-fatigue health-product containing or food.
The present invention is solved the problem by following technological means:
A kind of anti-fatigue medicament, described anti-fatigue medicament, by weight percentage, comprises following component:
Lepidinm meyenii Walp 50%;
Cordyceps militaris 25%;
Radix Panacis Quinquefolii 25%.
Further, also pharmaceutic adjuvant is comprised in described medicine.
Further, the dosage form of described medicine comprises oral liquid, beverage, tablet, capsule, spray or cutaneous permeable agent.
Further, the mode of taking of described medicine is every day 1 ~ 3 time, each 100-1000mg/kg the weight of animals.
Further, the administering mode of described medicine is oral or external.
A preparation method for anti-fatigue medicament, described preparation method is: be dissolved in normal saline or deionized water by Lepidinm meyenii Walp, Cordyceps militaris and Radix Panacis Quinquefolii according to part by weight 50%:25%:25% mixing, then adds excipient substance composition compound formulation.
A purposes for anti-fatigue medicament, anti-fatigue medicament is applied to prepares anti-fatigue health-product containing or food.
Further, described anti-fatigue medicament is applied to and corrects sub-health state or treatment chronic fatigue syndrome; Described correction sub-health state comprises increases hepatic glycogen content, increase full blood lactic content or reduction Plasma Urea nitrogen content.
A kind of anti-fatigue medicament provided by the invention, by Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction, experimental result shows, have and extend middle age and Aged Mice walking weight load, increase liver glycogen reserves, reduce lactic acid, urea nitrogen content, have that consumption is little, safety, injectable, can be oral etc. advantage, there is larger health care and clinical value.This anti-fatigue medicament provided by the invention can be applicable to prepare anti-fatigue health-product containing or food.
Accompanying drawing explanation
Figure 1A is that a kind of anti-fatigue medicament of the present invention is to first lumbar injection experimental result of mice burden swimming time;
Figure 1B is that a kind of anti-fatigue medicament of the present invention is to the oral experimental result of mice burden swimming time second batch;
Fig. 1 C is that a kind of anti-fatigue medicament of the present invention is to mice burden swimming time the 3rd batch oral treating chronic effort syndrome experimental result;
Fig. 2 A is that a kind of anti-fatigue medicament of the present invention is to first lumbar injection experimental result of mice liver glycogen reserves;
Fig. 2 B is that a kind of anti-fatigue medicament of the present invention is to the oral experimental result of mice liver glycogen reserves second batch;
Fig. 2 C is that a kind of anti-fatigue medicament of the present invention is to the oral treating chronic effort syndrome experimental result of mice liver glycogen reserves the 3rd batch;
Fig. 3 A is that a kind of anti-fatigue medicament of the present invention is to first lumbar injection experimental result of Mouse whole blood lactate level;
Fig. 3 B is that a kind of anti-fatigue medicament of the present invention is to the oral experimental result of Mouse whole blood lactate level second batch;
Fig. 3 C is that a kind of anti-fatigue medicament of the present invention is to the oral treating chronic effort syndrome experimental result of Mouse whole blood lactate level the 3rd batch;
Fig. 4 A is a kind of anti-fatigue medicament of the present invention first lumbar injection experimental result to mice plasma urea nitrogen levels;
Fig. 4 B is the oral experimental result of the second batch of a kind of anti-fatigue medicament of the present invention to mice plasma urea nitrogen levels;
Fig. 4 C is that a kind of anti-fatigue medicament of the present invention is to the 3rd of mice plasma urea nitrogen levels the batch of oral treating chronic effort syndrome experimental result.
Detailed description of the invention
The invention discloses a kind of anti-fatigue medicament and its production and use, those skilled in the art can use for reference present disclosure, and suitable improving technique parameter realizes.Special needs to be pointed out is, all similar replacements and change apparent to those skilled in the art, they are all deemed to be included in the present invention.Method of the present invention and application are described by preferred embodiment, related personnel obviously can not depart from content of the present invention, spirit and scope methods and applications as herein described are changed or suitably change with combination, realize and apply the technology of the present invention.
Below with reference to accompanying drawing, the present invention is described in detail, and swimming with a load attached to the body is the important indicator evaluating body movement fatigue, and the length of swimming time can reflect the degree of animal movement fatigue.The glycogen of cylinder storage is the main energy sources of mouse movement, and body strenuous exercise needs to consume a large amount of glycogen, and therefore glycogen deposit is also the important indicator evaluating body fatigue resistance.Lactic acid occupies an important position in body energy supply system, and it is the end product of glycolysis energy supply, is again the important oxygen metabolism substrate in aerobic metabolism energy supplying system, and lactic acid can in liver by sugar heteroplasia role transformation be glucose energy supply.If but produce excessive lactic acid in body. H+ concentration rising .pH in muscle can be made to decline, and then cause a series of Biochemical changes, will fatigue be caused.Research display, the increase of blood urea nitrogen (BUN) and body are negative correlation to load performance, and body BUN content increases with the increase of sports load, so BUN is ideal, sensitive fatigue index.
In some embodiments of the invention, described resisting fatigue is for correcting sub-health state or treatment chronic fatigue syndrome.
In some embodiments of the invention, described correction sub-health state is for increasing hepatic glycogen content, increasing full blood lactic content or reduce Plasma Urea nitrogen content.
As preferably, Lepidinm meyenii Walp provided by the invention (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction are prepared in the purposes of anti-fatigue medicament, and described medicine also comprises pharmaceutically acceptable adjuvant.
In some embodiments of the invention, the preparation method of described medicine: a certain amount of NADPH Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii mixing are dissolved in normal saline or deionized water, can apply separately or form compound formulation with other active substance.
In some embodiments of the invention, the dosage form of described medicine is oral liquid, beverage, tablet, capsule, spray or cutaneous permeable agent.Find through test, the feature of Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction resisting fatigue is not by the impact of dosage form, and the acceptable dosage form of any medicine all can reach close effect, all within protection scope of the present invention,
The present invention is in this no limit.
In some embodiments of the invention, the administering mode of described anti-fatigue medicament is every day 1 ~ 3 time, each this medicament mixed of 100 ~ 1000mg preparation/kg the weight of animals.
In some embodiments of the invention, described medicine administering mode for injection and oral.The acceptable administering mode of any medicine all can reach close effect, and all within protection scope of the present invention, the present invention is in this no limit.
The invention provides a kind of anti-fatigue medicament.Test shows, lumbar injection gives this anti-fatigue medicament mixed liquor of the present invention and has the trend extending the mice burden swimming time, and this trend is dose dependent; Compared with eontrol group, oral give anti-fatigue medicament mixed liquor of the present invention after the mice burden swimming time present dose dependent extend, Analysis of variance, in, heavy dose of group have significant difference (p < 0.05) compared with control matched group.Compared with control group, the mice burden swimming time of model group obviously declines, and oral give described anti-fatigue medicament mixed liquor after the mice burden swimming time have obvious prolongation compared with model group.
Compared with control group, no matter be injection or orally give anti-fatigue medicament mixed liquor, Mouse Liver glycogen content all significantly increases, wherein, in drug administration by injection, dosage group and matched group difference reach significance level (Fig. 2 A), oral administration heavy dose group reaches significant level (Fig. 2 B) with matched group difference, there is statistical significance (p < 0.05), in the experiment for the treatment of chronic effort syndromes models, oral administration small dose group and model group difference reach significant level (Fig. 2 C), there is statistical significance (p < 0.05).
After injection gives anti-fatigue medicament mixed liquor, compare with control group, full blood lactic content obviously declines, with middle dosage and heavy dose the most remarkable (p < 0.05); Compared with control group, oral give anti-fatigue medicament mixed liquor after full blood lactic content decline all to some extent, but not statistically significant (p > 0.05).Compared with model group, oral give anti-fatigue medicament mixed liquor after Mouse whole blood lactic acid content have obvious prolongation, have statistically significant meaning (p < 0.01).
Anti-fatigue medicament mixed liquor of the present invention each dosage group Plasma Urea nitrogen content comparatively control group is compared and is declined all to some extent.In Analysis of variance drug administration by injection (Fig. 4 A), dosage group and matched group have highly significant, oral administration (Fig. 4 B) heavy dose group has highly significant (p < 0.05) with matched group, oral administration treating chronic effort syndrome (Fig. 4 C) heavy dose of group has downward trend compared with model group, but not statistically significant.
Comprehensive above-mentioned experimental result, this anti-fatigue medicament provided by the invention obviously can extend the mice burden swimming time, improves tired mice liver glycogen reserves, reduce tired mice lactic acid and urea nitrogen content, and prompting the present invention has obvious antifatigue effect.
Anti-fatigue medicament provided by the invention former medicine used and adjuvant, preparation all can be buied by market.
Below in conjunction with embodiment, set forth the present invention further:
Embodiment 1
1 materials and methods
1.1 samples:
1.2 laboratory animals: middle age age in May male ICR mouse; Age in August Old Male C57 mice.
1.3 instruments and reagent: the long microplate reader of swimming trunk, galvanized wire, all-wave, constant water bath box, centrifuge, hepatic glycogen detection kit (build up by Nanjing, article No. A043), lactate acid detection kit (build up by Nanjing, article No. A019-1), blood urea nitrogen test kit (build up by Nanjing, article No. C013-1), SOD detection kit (build up by Nanjing, article No. A001-1), MDA detection kit (Nanjing is built up, article No. A003-1).
1.4 experimental techniques:
A. first: by 60 the middle age in male age in May ICR mice be divided into 4 groups at random, often organize 15.The medicine of small dose group intraperitoneal injection 200mg/kg, the medicine of middle dosage intraperitoneal injection 400mg/kg, the medicine of heavy dose of intraperitoneal injection 600mg/kg.Control group gives the normal saline of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
B. second batch: old for 100 male ages in August C57 mice is divided into 4 groups at random, often organizes 20.The medicine of small dose group gavage 200mg/kg, the medicine of middle dosage gavage 400mg/kg, heavy dose of medicine of filling with 600mg/kg.Control group gives the water of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
C. the 3rd batch: by 80 the middle age in male age in May ICR mice be divided into 4 groups at random, often organize 20.Raise 14 days under Control group home; its excess-three group carries out chronic fatigue syndrome modeling: every morning, 9:00 to 11:00 fettered; each one hour; it is 35cm that mice is put into the depth of water by every afternoon; water temperature is force swimming 1 hour, continuous modeling 14 days in the swimming trunk of 21 ± 1 DEG C.Administration from the 15th day, the medicine of low dose of gavage 200mg/kg, the medicine of heavy dose of gavage 600mg/kg.Control group gives the water of same volume.Be administered once in every morning 10:00 to 11:00, successive administration 7 days.
1.4.1 swimming with a load attached to the body experiment
After last gives medicine 30min, bear the galvanized wire of 4% quality of its body weight to mouse tail.Mice being put into the depth of water is 35cm, and water temperature is the interior swimming of swimming trunk of 21 ± 1 DEG C, until power exhausts.The criterion that power exhausts is do not emerge in mouse head submerged 10s, and record power exhausts the time.
1.4.2 hepatic glycogen measures
After mice burden swimming, have a rest 10 minutes, by sacrifice after plucking eyeball blood sampling.Take out liver, blot with filter paper again with after normal saline rinsing, accurately take 50mg liver.The mensuration of liver hepatic glycogen is carried out according to test kit description.
1.4.3 full blood lactic measures
After mice burden swimming, have a rest 10 minutes, extract eyeball and get blood, the mensuration of carrying out full blood lactic is described according to test kit.
1.4.4 blood plasma index determining
After mice burden swimming, have a rest 10 minutes, eyeball is taken a blood sample, and with 3500 leaving the heart and isolate blood plasma after 10 minutes after the anticoagulant of EDETATE SODIUM salt, carries out the mensuration of plasma urea nitrogen according to test kit description.
2 results
2.1 mice burden swimming timings
Fig. 1 represents the impact of anti-fatigue medicament on the mice burden swimming time.Wherein Figure 1A is first lumbar injection experimental result; Figure 1B is the oral experimental result of second batch, and * represents that p < 0.05 compares with control group; C is the 3rd batch of oral treating chronic effort syndrome experimental result.As can be seen from Figure 1A, lumbar injection gives Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction and has the trend extending the mice burden swimming time, and this trend is dose dependent; As can be seen from Figure 1B, compared with control group, oral give Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction after the mice burden swimming time present dose dependent extend, Analysis of variance, in, heavy dose of group have significant difference (p < 0.05) compared with control matched group.As can be seen from Fig. 1 C, compared with control group, the mice burden swimming time of model group obviously declines, and oral give Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction after the mice burden swimming time have obvious prolongation compared with model group.
2.2 Mouse Liver glycogens measure
Fig. 2 represents the impact of anti-fatigue medicament on mice liver glycogen reserves, and wherein Fig. 2 A is first lumbar injection experimental result, and * represents p < 0.05, compares with control group; Fig. 2 B is the oral experimental result of second batch, and * represents p < 0.05, compares with control group; Fig. 2 C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * represents p < 0.05, compares with model group.As seen from Figure 2, compared with control group, no matter be injection or orally give Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction, Mouse Liver glycogen content all significantly increases, wherein, in drug administration by injection, dosage group and matched group difference reach significance level (Fig. 2 A), oral administration heavy dose group reaches significant level (Fig. 2 B) with matched group difference, there is statistical significance (p < 0.05), in the experiment for the treatment of chronic effort syndromes models, oral administration small dose group and model group difference reach significant level (Fig. 2 C), there is statistical significance (p < 0.05).
2.3 Mouse whole blood Plasma lactates
Fig. 3 represents the impact of anti-fatigue medicament on Mouse whole blood lactate level.Wherein Fig. 3 A is first lumbar injection experimental result, and * represents p < 0.05, compares with control group; Fig. 3 B is the oral experimental result of second batch, and C is the 3rd batch of oral treating chronic effort syndrome experimental result, and * * represents p < 0.01, compares with model group.As can be seen from Fig. 3 A, after injection gives Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction, compare with control group, full blood lactic content obviously declines, with middle dosage and heavy dose the most remarkable (p < 0.05); As can be seen from Fig. 3 B, compared with control group, oral give Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction after full blood lactic content decline all to some extent, but not statistically significant (p > 0.05).As can be seen from Fig. 3 C, compared with model group, oral give Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction after Mouse whole blood lactic acid content have obvious prolongation, have statistically significant meaning (p < 0.01).
2.4 mice plasma urea nitrogen contents measure
Fig. 4 represents the impact of anti-fatigue medicament on mice plasma urea nitrogen levels.Wherein Fig. 4 A is first lumbar injection experimental result, and * represents p < 0.05, compares with control group; Fig. 4 B is the oral experimental result of second batch, and * represents p < 0.05, compares with control group; Fig. 4 C is the 3rd batch of oral treating chronic effort syndrome experimental result.As seen from Figure 4, Lepidinm meyenii Walp (Maca), Cordyceps militaris and Radix Panacis Quinquefolii use in conjunction each dosage group Plasma Urea nitrogen content comparatively control group compare and decline all to some extent.In Analysis of variance drug administration by injection (Fig. 4 A), dosage group and matched group have highly significant, oral administration (Fig. 4 B) heavy dose group has highly significant (p < 0.05) with matched group, oral administration treating chronic effort syndrome (Fig. 4 C) heavy dose of group has downward trend compared with model group, but not statistically significant.
Comprehensive above-mentioned experimental result, this anti-fatigue medicament provided by the invention obviously can extend the mice burden swimming time, improves tired mice liver glycogen reserves, reduce tired mice lactic acid and urea nitrogen content, and prompting the present invention has obvious antifatigue effect.
The treatment of the resisting fatigue syndrome of this anti-fatigue medicament obtains similar effect.
The above is only the preferred embodiment of the present invention; it should be pointed out that for those skilled in the art, under the premise without departing from the principles of the invention; can also make some improvements and modifications, these improvements and modifications also should be considered as protection scope of the present invention.
Claims (8)
1. an anti-fatigue medicament, is characterized in that: described anti-fatigue medicament, by weight percentage, comprises following component:
Lepidinm meyenii Walp 50%;
Cordyceps militaris 25%;
Radix Panacis Quinquefolii 25%.
2. a kind of anti-fatigue medicament according to claim 1, is characterized in that: also comprise pharmaceutic adjuvant in described medicine.
3. a kind of anti-fatigue medicament according to claim 1, is characterized in that: the dosage form of described medicine comprises oral liquid, beverage, tablet, capsule, spray or cutaneous permeable agent.
4. a kind of anti-fatigue medicament according to claim 1, is characterized in that: the mode of taking of described medicine is every day 1 ~ 3 time, each 100-1000mg/kg the weight of animals.
5. a kind of anti-fatigue medicament according to claim 3, is characterized in that: the administering mode of described medicine is oral or external.
6. the preparation method of the arbitrary described anti-fatigue medicament of claim 1-5, it is characterized in that: described preparation method is: NADPH Lepidinm meyenii Walp, Cordyceps militaris and Radix Panacis Quinquefolii are dissolved in normal saline or deionized water according to part by weight 50: 25: 25 mixing, then add excipient substance composition compound formulation.
7. a purposes for the arbitrary described anti-fatigue medicament of claim 1-5, is characterized in that: anti-fatigue medicament is applied to prepares anti-fatigue health-product containing or food.
8. the purposes of a kind of anti-fatigue medicament according to claim 7, is characterized in that: described anti-fatigue medicament is applied to corrects sub-health state or treatment chronic fatigue syndrome; Described correction sub-health state comprises increases hepatic glycogen content, increase full blood lactic content or reduction Plasma Urea nitrogen content.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510763099.5A CN105213456A (en) | 2015-11-10 | 2015-11-10 | A kind of anti-fatigue medicament and its production and use |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510763099.5A CN105213456A (en) | 2015-11-10 | 2015-11-10 | A kind of anti-fatigue medicament and its production and use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105213456A true CN105213456A (en) | 2016-01-06 |
Family
ID=54982972
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510763099.5A Pending CN105213456A (en) | 2015-11-10 | 2015-11-10 | A kind of anti-fatigue medicament and its production and use |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105213456A (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074656A (en) * | 2016-07-27 | 2016-11-09 | 江苏七O七天然制药有限公司 | A kind of Chinese medicinal capsule and preparation technology thereof |
| CN111518264A (en) * | 2020-04-30 | 2020-08-11 | 南通大学 | Heart-strengthening anti-fatigue polymer nano-particles and preparation method thereof |
| CN111679042A (en) * | 2020-06-12 | 2020-09-18 | 黑龙江省四宝生物科技股份有限公司 | Research method for anti-fatigue pharmacological effect of oviductus ranae freeze-dried powder |
| CN112972522A (en) * | 2021-02-26 | 2021-06-18 | 拉萨经济技术开发区一六藏医药研发有限公司 | Mint buccal tablet and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813693A (en) * | 2012-08-24 | 2012-12-12 | 舒熳 | Novel composite and preparation method and application thereof |
| CN103251052A (en) * | 2013-05-23 | 2013-08-21 | 昆明宝特药用植物研究开发有限公司 | Lepidium meyenii walp and cordyceps militaris health-care food and preparation method thereof |
| KR20140103572A (en) * | 2013-02-18 | 2014-08-27 | (주)엠피위즈 | A functional liquid composition comprising arginine, maca powder extract, citric acid and polydextrose as main ingredients |
-
2015
- 2015-11-10 CN CN201510763099.5A patent/CN105213456A/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN102813693A (en) * | 2012-08-24 | 2012-12-12 | 舒熳 | Novel composite and preparation method and application thereof |
| KR20140103572A (en) * | 2013-02-18 | 2014-08-27 | (주)엠피위즈 | A functional liquid composition comprising arginine, maca powder extract, citric acid and polydextrose as main ingredients |
| CN103251052A (en) * | 2013-05-23 | 2013-08-21 | 昆明宝特药用植物研究开发有限公司 | Lepidium meyenii walp and cordyceps militaris health-care food and preparation method thereof |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106074656A (en) * | 2016-07-27 | 2016-11-09 | 江苏七O七天然制药有限公司 | A kind of Chinese medicinal capsule and preparation technology thereof |
| CN111518264A (en) * | 2020-04-30 | 2020-08-11 | 南通大学 | Heart-strengthening anti-fatigue polymer nano-particles and preparation method thereof |
| CN111518264B (en) * | 2020-04-30 | 2022-03-01 | 南通大学 | Heart-strengthening anti-fatigue polymer nano-particles and preparation method thereof |
| CN111679042A (en) * | 2020-06-12 | 2020-09-18 | 黑龙江省四宝生物科技股份有限公司 | Research method for anti-fatigue pharmacological effect of oviductus ranae freeze-dried powder |
| CN112972522A (en) * | 2021-02-26 | 2021-06-18 | 拉萨经济技术开发区一六藏医药研发有限公司 | Mint buccal tablet and preparation method and application thereof |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN107581619A (en) | A kind of antifatigue anti senility sea cucumber oyster peptide complex capsule and preparation method thereof | |
| CN107691952A (en) | A kind of resisting kinetic fatigue, the composition for promoting postexercise recovery and preparation method thereof | |
| CN102526478B (en) | Formula of health-care medicine with functions of strengthening immunity and reducing blood sugar | |
| CN102526479B (en) | Health-care medicine formula with functions of enhancing immunity and lowering blood sugar | |
| CN103070880B (en) | Application of acanthopanax trifoliatus polysaccharide in preparing medicine for treating diabetes | |
| CN110237104A (en) | It is suitable for the health-oriented products composition of adult female, old man and sub-health state crowd | |
| CN105532998A (en) | Health-care tea containing cordyceps militaris and preparation method thereof | |
| CN105213456A (en) | A kind of anti-fatigue medicament and its production and use | |
| CN102450718B (en) | Pulse sports beverage and preparation method thereof | |
| CN107212401A (en) | Composition for relieving physical fatigue and its preparation and preparation method | |
| CN104740451B (en) | A kind of Chinese medicine composition for treating hyperuricemia and its application | |
| CN104336174A (en) | Rhodiola rosea and milk vinegar contained green tea health beverage | |
| CN103704711B (en) | Granules with anti-fatigue and health-care function | |
| CN105341893A (en) | Composition for assisting in reducing blood glucose and application | |
| CN107912773A (en) | A kind of preparation for being used to alleviate physical fatigue | |
| CN106924548A (en) | The medicine and preparation method of a kind of fatigue-relieving | |
| CN110679815A (en) | Medicinal and edible compound health-care beverage with anti-fatigue and anti-hypoxia functions and preparation method thereof | |
| CN107303386A (en) | A kind of preparation method for being used to treat the low oral liquid of leucocyte | |
| CN107242563A (en) | A kind of fatigue resistant health food and preparation method thereof | |
| CN104814975A (en) | Anti-fatigue uses of rubus idaeus polysaccharides | |
| CN104306390A (en) | Application of reduced coenzyme II | |
| CN103478703A (en) | Health food with fatigue resistance function and preparation method thereof | |
| CN107281390A (en) | It is a kind of for Chinese medicine composition of health care and preparation method thereof | |
| CN105191859A (en) | Production method of low-cholesterol potassium-rich carotene-rich egg | |
| CN101642528B (en) | Production process of compound soft ginsengs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20160106 |
|
| WD01 | Invention patent application deemed withdrawn after publication |